RxDoctor Payments Data

Sharyna Rosati, PA

Medical · Pittsburgh, PANPI 1588053607

Payments from drug & device makers

$3,328in general payments, 2019–2025

Across 168 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$822
  • AstraZeneca$481
  • Novartis$396
  • Scpharmaceuticals Inc.$264
  • Johnson & Johnson$242
  • Boston Scientific$215
  • plus $908 from 20 others

What the payments were for

  • Food & beverage$3,30899%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,328 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$27,778
Medicare patients
234
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$139,714
EntrestoSacubitril/Valsartan86$85,107
JardianceEmpagliflozin61$67,650
FarxigaDapagliflozin Propanediol46$40,523
BrilintaTicagrelor60$34,340
Repatha SureclickEvolocumab33$31,569
XareltoRivaroxaban22$18,213
Rosuvastatin Calcium249$3,392
Bumetanide56$2,669
Metoprolol Succinate202$2,236
Atorvastatin Calcium184$2,012
Furosemide351$1,442
Ranolazine ErRanolazine26$1,362
Dofetilide12$1,069
Potassium Chloride86$992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$139,714195 claims
NovartisEntresto$396$85,10786 claims
AstraZenecaFarxiga, Brilinta$481$74,863106 claims
Boehringer IngelheimJardiance$822$67,65061 claims
Johnson & JohnsonXarelto$242$18,21322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →